Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug ...Middle East

Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022 REHOVOT, Israel, July 11, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd....

Hence then, the article about biomica announces successful enrollment of first patient in its phase i study of microbiome based immuno oncology drug was published today ( Monday 11/07/2022 - 03:13 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug )

Also on site :

• Iran’s new security boss Mohammad Zolghadr: Why his appointment matters
• UK ‘runs out’ of warships – leaving Germany to take over key Nato mission
• Kim Jong Un uses Iran war to justify North Korea’s decision to keep its nuclear weapons